House of Commons Hansard #85 of the 39th Parliament, 2nd Session. (The original version is on Parliament's site.) The word of the day was safety.

Topics

Food and Drugs ActGovernment Orders

3:40 p.m.

Liberal

Robert Thibault Liberal West Nova, NS

Mr. Speaker, I thank all members of the House.

I do not want to shock the minister while he is still present in the House, but it will come as very difficult news to him that for two days in a row we have to find some level of agreement with the bill that he proposes to the House of Commons. I am looking forward to this bill being at committee and to having the opportunity to further explore it.

I am pleased with the answer he gave to the member for Mississauga South. It is consistent with the discussion I had with the parliamentary secretary as to the fears out there about natural health products and natural therapeutic products not being targeted by this bill. I think that fear was out there, so I think this will be necessary. As I understand it, we can be assured of the government's cooperation if modifications have to be made in the definitions or in the bill so that this can be clearly drawn out.

That leaves one area of concern that I have been receiving as critic and which members undoubtedly will hear about. It is the question of direct to consumer advertising. While I understand from the bureaucrats or the minister's officials that there is no intention in this bill to permit direct to consumer advertising, it does somewhat change the way it is dealt with.

In the past it was directly in the bill. The bill said that the only advertising on prescription products would be the name, quantity and price. They were the only things that could be advertised. In this case, my understanding of it is that this gives the governor in council the potential to write regulations concerning advertising.

My understanding is that it is not the intent to open up the advertising, but it does take it out of the hands of Parliament and of the committee. That would cause some concern, so I hope that the government, at committee level, will be willing to look at some modifications to the bill, some amendments that might clarify this.

It could be done in one of two ways. One is that we could do the process that we have used in certain elements of the Health Act, which is to bring the regulations to committee for approval. We could limit it to those regulations concerning advertising, because it does not have to be all the regulations permitted under the act, or an amendment straight to the act. I will give some time for the government to consider those amendments before it comes to the committee. Hopefully, they will be negotiated amendments. If not, I am sure we will have some present.

That being said, I think the principles of this bill are quite good. This is not a bill that has been dreamt up in the last few weeks by the government. This bill is a result of a process of discussions and consultations that has been going on since 2003. These are part of the process that was known at the time as the smart regulations process. We were looking at regulatory reforms to the Government of Canada acts that necessitated those regulations to see if there was not a better way to do it, to be competitive internationally and domestically, and to at the same time protect Canadians.

One of the elements that comes in here is drug safety. The assurance of drug safety is very difficult. As the minister pointed out, the test on permitting or licensing of pharmaceutical products is whether the potential benefits outweigh the potential risks. We do not necessarily know when that first evaluation is done what the use of that pharmaceutical product will be in time, whether it will evolve from when the original clinical trials were done, and whether other drugs or therapies will come on stream that might interact with it. We do not know that.

Here we are going with the principle that has been known as progressive licensing and is now termed life cycle approvals or a life cycle approach. I do not know what it could be called that would reflect its true nature, but what it does is say that to get on the market initially the product has to meet the same safety criteria as it is currently meeting. The criteria are not relaxed.

Once the product is on the market, Health Canada has the ability to order further clinical trials or withdraw the licence if there is no compliance. I think that is important, because there could have been such a strict restrictive process, so as to assure absolute safety, that no new pharmaceuticals would ever come on the market.

However, with this process, we assure the safety of the product through clinical trials, and then we have time to do the evaluation as it is being used in the market, because the absolute use might be different from the use that had been foreseen. We heard at committee that the United States food and drug regulations use the 10,000 dosage system. After 10,000 dosages, they do a re-evaluation. Here, it could be different for any therapies.

However, once the experts at Health Canada see how a drug is evolving in its use, they can order further clinical trials at any time. I think it is important to try to understand what this means.

Number one, we know that almost no pharmaceuticals, and I could almost say zero, are approved for use by children. They are very seldom approved for use in pediatrics because it is so difficult to do clinical trials for pediatrics. The clinical trials before the first approval of a drug are done with adults. Then, over time, dosages or uses of prescriptions are studied by specialists in their work. When they find there is some value for use in pediatrics, they try to find the right dosage.

A drug might be developed for one specific use. For example, we have heard about Viagra being used in pediatric care, and while a drug might be developed for one specific use, it can be found through time that it is even more useful for other conditions that had not been considered. This is called off-label use.

I remember reading not so long ago about a cancer drug being used for macular degeneration. It was just as effective as the drug that had been used for macular degeneration. Thus, we can see how a drug might be used in a therapy other than the purpose for which it had its first clinical trials.

We now have the ability, with this bill, for Health Canada to order clinical trials in that area of use and in that population. If we discover with time that the major use of a certain therapy or pharmaceutical product ends up being done by seniors, those between the ages of 50 and 65, then perhaps Health Canada could order that a specific clinical trial be done in that area. If it is for people who have certain diseases and there are risks, we can do those things.

That is a logical, smart approach, which permits the drug to come on the market under the same criteria that it does now. This is what I think Canadians have to understand: this is not the relaxation of the initial criteria. It is a reasonable, intelligent way of monitoring the use of that product over time and changing the licensing standards.

Again, I think it is important to respond to the scare that is being put out there, because there are a lot of Canadians who are finding very good benefits in using non-prescription health products, therapeutic products, natural health products, organics, or whatever we want to call them. They are under different names. People are concerned when they see this bill that it might mean they can no longer access those products. I have had calls about this, as all the members of Parliament will.

I take the minister at his word. When I read the bill, I did not see any effect on the natural health product directorate and I did not see that these products were moved, but the fear is out there among Canadians and I think we will have to ensure, before the bill goes through the House of Commons and the Senate, that it is cleared up.

Yesterday when we were looking at Bill C-52, I raised a question on the power to recall and said that we have to be careful. We have to be careful that the power to recall does not become an obligation to recall. If we give the power to the minister and his inspectors, we have to make sure that this power is used only when all other methods fail and only when all other methods have been attempted, because we do not know of any problems we have had so far. So far, negotiations have been successful.

I see that my time has run out. I thank members for their attention.

Food and Drugs ActGovernment Orders

3:50 p.m.

Charleswood—St. James—Assiniboia Manitoba

Conservative

Steven Fletcher ConservativeParliamentary Secretary for Health

Mr. Speaker, I thank the member for his speech and for what appears to be a very thoughtful and cooperative approach to this government legislation. I think it demonstrates that this Parliament has the potential to work very well in that together we can move forward legislation that is important for Canadians.

I have a question for the member. The life cycle approach has a lot of merit, I think, and we have heard the minister speak to that. I wonder if the member would agree that the life cycle approach is the right approach to take when it comes to products such as those we are discussing today.

Food and Drugs ActGovernment Orders

3:50 p.m.

Liberal

Robert Thibault Liberal West Nova, NS

Yes, Mr. Speaker, I believe it is. It gives the tools to the Department of Health. It gives the department the potential to ensure the safety of a product as its use evolves. Currently, all we can do is look at whether the product is safe for the use for which the application was made. With time, the use might become completely different than what was considered when that product was developed and when clinical trials were happening.

As I mentioned in my speaking notes, if we want to make the initial licensing so restrictive and so strict as to ensure our safety on all uses in the future, no therapies would ever come to market. No new drugs and no new therapies would ever become commercialized and Canadians would not have access to them.

I think this is a logical way to do it. It is a smart regulation. I do not know why we would ever have accepted stupid regulation, but this is an intelligent way of having regulation and ensuring safety.

It is important to have the necessary tools and the will at the Department of Health to impose those further clinical trials after the drug has been on the market for a certain amount of time. Again, that is going to require some cooperation from pharmaceutical producers.

Food and Drugs ActGovernment Orders

3:50 p.m.

Liberal

Paul Szabo Liberal Mississauga South, ON

Mr. Speaker, I appreciate the commentary of the member, who is the health critic for the official opposition.

We have had some experience in the past through the reproductive technologies bill. It was supposed to take two years for regulations to come forward, but several years later we still do not have all of the regulations. I see here that there are other regulations.

My question for the member really has to do with the fact that half of the clauses in the bill would make consequential amendments to other acts. I do not know how many members of Parliament would be able to inform themselves as to the nature of those changes and whether they should access all the other bills to see if the changes would be meaningful.

Will the member undertake as part of the review, should the bill pass at second reading and go to committee, to ensure that Health Canada would provide to committee, which would therefore make it accessible to other members of Parliament, a proper explanation as to the rationale for the consequential amendments to other acts so we can be absolutely assured that we do not have other areas that should be examined and may impact areas of concern to the public?

Food and Drugs ActGovernment Orders

3:50 p.m.

Liberal

Robert Thibault Liberal West Nova, NS

Mr. Speaker, that is a very good point. It is a point that is often overlooked by the House when we approve a bill. We saw it with Bill C-10. One small element of a regulation was missed by the House, but luckily it was picked up by the Senate, as it would have led to censorship in our film and television production.

In this case, there are a number of acts, such as the Canadian Food Inspection Agency Act, the Fisheries Act, and some agricultural aspects, which the next speaker will certainly want to raise. The joint administration and the cross-regulation between the Health Act, the Food and Drugs Act and other acts necessitate all these amendments.

These are some of the things that we certainly will be studying at committee. We will ask the Library of Parliament for the analysis, which it does very well. We have had the preliminary one. As well, witnesses will appear who can show us if there will be difficulties within their areas of jurisdiction or administration.

Food and Drugs ActGovernment Orders

3:55 p.m.

Liberal

Wayne Easter Liberal Malpeque, PE

Mr. Speaker, I am pleased to speak to Bill C-51. In fact, as my colleague from West Nova said earlier in his remarks, these are two bills in a row, Bill C-51 and Bill C-52, that we are certainly most interested in moving forward to committee for further technical analysis and more research, but we do believe the bills in principle need to be carried forward.

The section of the bill with which I really want to deal is on the food side of it. I think there is strong interest in ensuring that products are indeed safe. I would say there is an almost public wave for stronger action in this regard. There has been the recent incidence of unsafe food. Health and consumer products have underscored the need to modernize the Food and Drugs Act. The fact of the matter is that the act was developed in 1953 and these amendments certainly update the bill.

Basically, the bill would amend the Food and Drugs Act and modernize the regulatory system for foods and therapeutic products. It would improve the surveillance of benefits and risks of therapeutic products through their life cycle. It is designed to increase compliance and enforcement measures by corporations to encourage them to report adverse reactions or potential health threats associated with market products. It would, I will admit, give substantial regulatory power to the minister.

I know there are some concerns about that. We have a number of letters already. That is why it is so important for the bill to go to committee relatively quickly, so that the witness lists can be prepared and those concerns can be addressed. We certainly support the idea of improving the safety and health of Canadians. We are committed to improving the safety and health of Canadians. We support measures to strengthen the regulatory system to ensure that Canadians are able to access the safest and most effective food in the world as well as with therapeutic products.

I want to turn mainly to the food area of the bill and that is in clauses 4 through to 6. The bill would create new offences relating to food, therapeutic products and cosmetics. It would require licensing for importing food and for the interprovincial trade in food.

In a previous Parliament there was Bill C-27. We in fact looked fairly extensively at the regulations surrounding the importing of food and the interprovincial trade in food. In all seriousness, there had to be improvements made in that area to ensure that imported food was safe and met the same kind of regulatory requirements as indeed Canadian food had to meet.

This bill in all areas would expand the regulatory authority, but in the food area it would expand the power of inspectors. I want to point out that it is not our intent nor do I believe it is the government's intent or even the bureaucracy's intent that the expansion of the powers of inspectors is to be overbearing. It is to ensure that the human resources and the authority are there to deal with some of the incidences that can happen on grocery store shelves or that imported food can face.

I would put a caveat in. Those of us who are on the agriculture committee know that certainly more human resources must be added to the Canadian Food Inspection Agency for it to do its job. The government did indicate the other day that there are some budgetary measures in that regard, but there do need to be the human and financial resources for the Canadian Food Inspection Agency to do its job and the additional authorities granted to it through this bill.

I also want to underline the fact that one of the concerns that we raised at our committee level was that these costs should not be passed on to primary producers. We have had enough of that. Primary producers should not be the ones bearing the costs for food inspections in this country. That is a public safety and health and safety issue. It is a public responsibility and we would hope that the government takes that seriously and funds the Canadian Food Inspection Agency appropriately to do its job.

The new prohibited activity in the bill really gives the government the authority to take action if someone knowingly provides the minister with false or misleading information relating to any matter in this bill, whether someone knowingly is tampering with a food, therapeutic product or a cosmetic, including tampering with a label or package.

A number of years ago, we heard about a substantial number of those where people, as a hoax or a threat or an act of terrorism really, had sent out the word over the media or email, or by other means, that they had in fact tampered with a food product on a grocery store shelf. That creates tremendous concern among the consuming public. It certainly creates difficulties for the businesses so affected. Under this bill, I do believe there is more authority for the authorities themselves to deal with those matters where there are hoaxes or threats, or indeed actual tampering with food itself.

The other area in clause 4 will also prohibit the importing of food that is injurious to human health. That is an important aspect of the bill that was not there previously in terms of the trade that goes on. It is very important that imported food be treated in the same way as domestic food on the grocery store shelves, and that action be taken against companies or individuals who may have both exported into this country or the company that imported the food that is injurious to human health. That is a very important measure.

We tend, in this country, to take our food system for granted. Canadian farmers provide the safest food in the world. The problem is they are certainly not paid well enough for it. Canadians only pay 13.5% of their income and by early February, their food bills are paid for the year. We do not want anything to happen on those grocery store shelves that will reflect badly on the Canadian primary producers.

The last point that I would make, as I see I am running out of time, is a point I made the other day, but I will make it again. Canadian farmers do face a double standard from their own government regulations. We must be on a level playing field with the rest of the world. We cannot add another regulatory burden.

Food and Drugs ActGovernment Orders

4:05 p.m.

Charleswood—St. James—Assiniboia Manitoba

Conservative

Steven Fletcher ConservativeParliamentary Secretary for Health

Mr. Speaker, I would like to point out to the member that $113 million over two years has been put aside in budget 2008. Naturally, we would like to thank the member for his support for that budget. I wonder if the member could explain his position on the life cycle approach and tell us if he supports his health critic on that approach to product safety.

Food and Drugs ActGovernment Orders

4:05 p.m.

Liberal

Wayne Easter Liberal Malpeque, PE

Mr. Speaker, I am glad to see that those resources are there. However, I want to point out to the parliamentary secretary that we have seen this in the past, both with the current government and previous governments. The way the system operates in Ottawa is that sometimes there is a small cost recovery fee or the government is in fact paying the fees for certain measures and after a while, as time goes on or the cost recovery fee goes up, the burden of cost is passed down to others in the industry. We want to ensure that does not happen in this case.

In terms of the health critic for the Liberal Party, on this side of the House we do not say “yes, sir” or “no, sir”. We have strong debates in caucus and we will on this issue. However, when the decision is made, we operate as a team, and certainly I will be supporting my health critic in this regard.

Food and Drugs ActGovernment Orders

4:05 p.m.

Conservative

James Lunney Conservative Nanaimo—Alberni, BC

Mr. Speaker, I appreciate the member's comments on the bill. I know the member comes from Prince Edward Island and I know that, having been out there, a lot of people in Prince Edward Island actually use natural health products.

He will remember, because I know this member has been in the House for a while, that over the years there have been discussions about the Food and Drugs Act and how to regulate natural health products. After a number of machinations, natural health products, which were promised to be a third category, ended up as a sub-category of drugs. Indeed, they have been regulated as a sub-class of drugs.

I wonder if the member has heard concerns from his constituents, as I certainly have, about the regulation of natural health products under this proposed bill. In fact, therapeutic products replace drugs and natural health products, so NHPs equal drugs and drugs equal NHPs except for the regulations. However, the bill has very serious and strong seizure, forfeiture regulations attached to this. Does the hon. member think it is appropriate for drugs to be applied to natural health products, is it a concern for him as we are hearing from some people across the country?

Food and Drugs ActGovernment Orders

4:05 p.m.

Liberal

Wayne Easter Liberal Malpeque, PE

Mr. Speaker, indeed, we are hearing, and we had a discussion here earlier among members on this side of the House, about the concern that is coming forward from people in the natural health products industry. In my overview of the bill, I do not think it hurts the natural health products industry or helps it at this point in time.

However, as the health critic said, it is extremely important when the bill gets to committee that witnesses be brought in and that they have their say. If there are concerns, they should be addressed. I think the natural health products industry is a growing industry. These are more natural products and they get us off the drug hook, if I can put it that way.

Food and Drugs ActGovernment Orders

4:10 p.m.

Conservative

The Acting Speaker Conservative Andrew Scheer

A very brief question or comment. The hon. member for Yukon.

Food and Drugs ActGovernment Orders

4:10 p.m.

Liberal

Larry Bagnell Liberal Yukon, YT

Mr. Speaker, actually, my question was not brief, so I guess I will ask the short part. I have two emails. The short one reads:

I am opposed to the police state powers in Bill C-51. I want my access to natural health products protected and there is something wrong with the state making personal health decisions for us. Health decisions are fundamental to our personal autonomy.

I wonder if the member has any comments to that email.

Food and Drugs ActGovernment Orders

4:10 p.m.

Liberal

Wayne Easter Liberal Malpeque, PE

Mr. Speaker, it is a legitimate question and it is one that should be addressed when the bill gets to committee with witnesses in that regard.

However, on the food side, which I generally talked about, we do need the authority as a government regulator to move rapidly if there are concerns in the system or a small issue becomes magnified and mushrooms into a huge issue.

I would suggest that those concerns should be addressed at committee. I do not believe there are police state powers in the bill.

Food and Drugs ActGovernment Orders

4:10 p.m.

Bloc

Christiane Gagnon Bloc Québec, QC

Mr. Speaker, I am pleased to speak to second reading stage of Bill C-51 to amend the Food and Drugs Act. We know this act has been around for 40 years and that not too many changes have been made to it with respect to food and drug safety.

Bill C-51 bears a strong resemblance and is closely related to Bill C-52, which seeks to better monitor products on the market and reassure the public about product safety.

Here the government is taking things a bit further. It wants to cover other products, including pharmacological products, and look at pharmacovigilance.

Why does the government want to modernize this act? Because the public is quite worried. In the past few months and years, it has come to our attention that some products are harmful to our health. Certain drugs have adverse effects causing death.

For example, there is Singulair produced by Merck Frosst. This is an asthma drug that causes suicidal ideation. Champix, an anti-smoking drug produced by Pfizer, also causes suicidal ideation and depression. What is more, anti-psychotic drugs for children apparently cause obesity. These are some of the harmful effects of taking those drugs.

More and more people are worried about some of the drugs on the market. Some consumer products, such as children's toys or toothpaste from South Africa, also contain toxic substances. Other products contain mercury. The government is introducing this bill, which it was asked to do, to reassure the public about drug safety.

The minister has been asked about this a number of times. In 2006, the Auditor General issued a scathing report saying the government should make some changes. The lack of control by the Canadian Food Inspection Agency was among the Auditor General's many criticisms. Even that agency admits that unsafe products may be found on the shelves and that the public has cause for concern.

Will the bill properly respond to this situation and ensure food and drug safety?

The minister probably wants to reassure citizens with his bill. The purpose of Bill C-52 is to increase the industry's accountability with regard to the food supply. The government may also require that food safety monitoring be implemented. To that end, it gives the minister the authority to conduct inspections at any time. It will also require the industry to report the adverse effects of consuming certain foods. It also provides for a tracing system not just for foods but also for cosmetics and therapeutic products.

Is this the right approach? The objectives are laudable. How will it be done? We know that a whole set of regulations will come after the bill. However, today, we cannot discuss the regulations because they are not available. We hope that they will be provided when the bill is studied in committee. With regard to the Assisted Human Reproduction Act, passed in 2004, only one regulation was submitted to committee review and we are still waiting for the regulations. We hope that the regulations will follow on the heels of the bill so that they may be debated in committee.

Will the government meet the expectations of Canadians?

In response to the fears surrounding the safety of food and therapeutic products, the Auditor General was headed in the right direction when she sounded the alarm for the government by asking it to increase human resources and particularly to provide funding for inspections.

We need only think of natural products, for example. We know that there are between 33,000 and 40,000 products waiting for inspection in order to be licensed because of the shortage of inspectors. This applies not just to natural products but in particular to foods and consumer products. The inspectors quite often do not have the requisite training to properly inspect all these products.

There was a call for better training for staff and better human resources. I am afraid that this objective is not met by this bill. We can see that resources are lacking, as I was saying. Concerns about these shortcomings were expressed not only by the Auditor General but also by the Canadian Food Inspection Agency.

Today, Bill C-51 goes one step further. In committee, we are studying aspects of post-market monitoring and pharmacovigilance. Over the past few months, we have met with experts and witnesses. We would have hoped to see Bill C-51 drafted along the lines that the committee suggested to the minister after it received recommendations from experts. However, he got a little ahead of the committee's work, and there was some duplication.

We are now considering this bill at second reading. We will vote in favour of the bill because we want it to be referred to committee for further study. That means that we will have to invite the same number of people, the same experts, to come tell us what they think about this bill. We would have hoped that the minister would have waited for our amendments and recommendations.

That is not what happened, so we hope that the minister will be open to some amendments to the bill in areas where he did not take into account all the concerns of the witnesses who appeared before the committee. We hope that the government will be open to these amendments. I am sure that amendments will be proposed, because the bill does not adequately address the issue of food and therapeutic product safety.

I would also like to talk about adverse drug reactions, which the bill addresses. Various experts commented on this and clarified things for us. That is what we would have liked to pass on to the minister before this bill was introduced. For example, consider hospitals' obligation to report on adverse drug effects, as set out in the bill. Many witnesses told us that that might not be the best way to go. Currently, between 1% and 10% of adverse effects are reported. Is the government hoping that by introducing this measure, that incidence will go up? Probably.

We would like to see greater interest in the reporting of adverse effects, but not just any old way. Some witnesses told us that hospitals may not have appropriate structures in place to fulfill this obligation. It might be too much red tape.

I do not know what kind of clarification the minister will provide on this issue. Regardless, we would have hoped to have had an opportunity to submit our recommendations after analyzing all of the testimony.

As I was saying, the bill also seeks to create a register of adverse reations.

We wonder about the reporting of serious and rare adverse reactions, but especially about how this information will be passed on so that health professionals are kept abreast of information from the adverse reaction register. The frequency of common adverse reactions is already known because of clinical trials. According to some witnesses, what is important is what we do not know, the unknown reactions.

With regard to mandatory reporting by hospitals, as I said, since all adverse reactions will have to be reported, not just unknown and more serious reactions, hospital pharmacists are afraid their workload will increase significantly. Should the emphasis be on the quantity or the quality of adverse reaction reports? An increase in the number of reports could dilute the most valuable information.

A number of witnesses told us that the focus should be on unexpected adverse reactions. Is the frequency of an adverse reaction important? These are questions we are still asking ourselves in committee. We believe that this issue has not yet been resolved. That is why we are going to question the government about this in committee.

For example, one witness, Bruce Carleton, a senior clinician scientist from the University of British Columbia and B.C. Children's Hospital, suggests looking at human genetics and drug biotransformation. According to Dr. Carleton, drug reactions have a genetic basis. If further genetic research were conducted, it would be possible to predict and avoid adverse drug reactions.

This is an indication of the complexity of detecting adverse reactions. We would have liked to see a more innovative, proactive approach that goes beyond just adverse drug reaction reporting. As I said, this is known as pharmacogenomics.

One of the major concerns we had in committee about the creation of a register of adverse effects and adverse reaction reporting by hospitals pertains to the method of post-market monitoring. As I said earlier, the effectiveness of post-market monitoring will depend on how the register of adverse drug effects is structured and on the effectiveness of feedback from health professionals, including pharmacists and physicians.

It is not enough to simply create registers and collect data. In her testimony on April 10, the Auditor General said that there were weaknesses in the analysis and interpretation of adverse events, and there was no proactive system to identify patterns that could signal a serious safety concern.

The committee's work could have enlightened the minister about this bill. As I was saying earlier, we would have liked for him to wait for our reactions and our recommendations after our three-month-long analysis on pharmacovigilance. Some witnesses also suggested that an independent evaluation board be created.

What about that? Will the bill cover that? We know that clinical trials are done by the manufacturers, and that often, a number of adverse effects are known, but are not revealed and the drug is put on the market. We would have liked to see an independent evaluation board, and a number of witnesses agreed.

The life cycle of a drug will supposedly be extended, but we would like this to be done not only by manufacturers, but also by an independent evaluation board throughout the life cycle of the drug. We know that drugs are often tested on certain patients, but other groups of people have not been tested—for example children and seniors—and often, these drugs have serious adverse effects if they are used.

The creation of a research centre of excellence, in partnership with our universities, has also been suggested. This centre could engage in pharmacoepidemiology studies that would be required by law and funded by the industry, but not conducted by the industry, which is currently the case. Another guide was suggested, one that would be much more proactive and independent in relation to the pharmaceutical industry.

Any mandatory adverse reaction report will be ineffective if not dealt with properly. That is more or less the conclusion reached by several witnesses who want the government to do something about this. Will Bill C-51 address all those concerns?

For now, as I said earlier, some drugs have been taken off the market, but they could have been not put on the market right away in the first place. The industry could have waited for further clinical trials to be done.

There are also fears that there is an attempt to shorten the process before a drug is put on the market. There are some fears about the life cycle of the drug and following it after it goes on the market. That is a step in the right direction, but there is also a fear that this would shorten the period before the certification of clinical trials. We heard this from several witnesses. Thus, the life cycle of a drug should not be an excuse for premarketing studies to be reduced nor for the door to be opened to such a possibility.

A number of witnesses have told us that they would like the minister to be open to certain amendments they would like to see made to this bill. It is hoped that the minister and this government will be open to the decision made during clause by clause consideration of the bill.

As I was saying earlier, the regulations are not yet available. Will they be satisfactory? It is hard to say. It is rather a blank cheque right now. We know that the regulation will give life to the bill.

The vote here in Parliament will send the bill to committee, as I think all hon. members want to address it. Work will be done in committee.

Nonetheless, we hope—I am saying this again because I do not want anyone to forget it—that the minister will be open to the various voices that have been heard. For three months, we have been studying the drug monitoring program and the new life cycle for drugs, which takes a different approach, namely that trials continue after the drug is put on the market, in the interest of human safety.

For example, we know that some people have died after taking certain drugs. We also know that often, for genetic reasons, some drugs should not be given to certain patients. There needs to be openness in order to better address this whole issue. We have to take into account all the problems we have in properly understanding the effects of drugs on patients, those who use these drugs.

Labelling was also discussed. Warnings have to be issued, for example, if a person is sick and there is a contraindication to taking a certain drug. We would hope that the minister is open to that and that this will address the entire problem.

We are in the process of reviewing this approach. Given the openness of the parliamentary secretary, who sits on our committee, he can relay the questions to the minister. We are counting on his openness in this matter and we hope he will be proactive and sympathetic to our demands.

Food and Drugs ActGovernment Orders

4:30 p.m.

NDP

Irene Mathyssen NDP London—Fanshawe, ON

Mr. Speaker, the New Democratic Party caucus also has concerns with regard to this legislation, specifically in the areas she addressed, and that is the safety of drugs and the shortcuts that can be taken in clinical trials.

I remind everyone that some years back the Liberals closed Health Canada drug labs and entered into what they called partnerships between drugs companies and Health Canada. That activity has compelled the NDP to take a very close look because it would seem to compromise the safety of some products.

Could the member opposite comment on that? Does she see a need to return to a more rigorous Health Canada review?

Food and Drugs ActGovernment Orders

4:30 p.m.

Bloc

Christiane Gagnon Bloc Québec, QC

Mr. Speaker, I thank my colleague for her question.

We are in the process of looking at pharmacovigilance, and a number of witnesses came to tell us that they would like to have an independent board. We hope that the government also wants to extend the life cycle when it comes to the safety of a pharmaceutical product.

We would like an independent body with the authority to oversee the products on the market. Witnesses told us that they do not want to decrease the amount of time required for clinical trials of drugs before they are put on the market. They also hope that an independent body will then be able to monitor these drugs.

Some drugs are subject to clinical trials, but their adverse effects are often kept secret. They are not known. How is it possible, for example, that 51% of drugs present serious side effects after being put on the market? Would it not be good for an independent body to also have the oversight on these clinical trials, instead of leaving it to private enterprise?

Food and Drugs ActGovernment Orders

4:30 p.m.

Charleswood—St. James—Assiniboia Manitoba

Conservative

Steven Fletcher ConservativeParliamentary Secretary for Health

Mr. Speaker, I assure the member that there are no shortcuts when it comes to clinical trials. In fact, the bill, through the life cycle approach, is much more effective in ensuring the safety of Canadians because it would allow the government to monitor the products after they reach the market.

I will also address a concern raised by the Bloc. Proactive measures have been taken by the minister and the government. It has been demonstrated with the presentation of Bills C-51 and C-52. It has been demonstrated again in budget 2008 in which $113 million has been invested to ensure that we will have a food and consumer safety action plan that is well funded.

Will the member agree that a life cycle approach is the right way to go and that it is important for the Minister of Health to have the ability, in rare but extreme cases, to remove a product off the shelf? Those are really the main points of the bill. I hope the member will be open to accepting that the government is on the right track without predetermining, what is so often the case, negativity.

Does the member agree with the life cycle approach and mandatory recall, if necessary?

Food and Drugs ActGovernment Orders

4:35 p.m.

Bloc

Christiane Gagnon Bloc Québec, QC

Mr. Speaker, I will reply to the Parliamentary Secretary for Health.

I am not negative; I am quite open. It is not about the life cycle approach. We have to look at the life cycle of a drug so that it is analyzed and tested even after being put on the market. I am saying that there are certain fears.

I believe that in a democracy we can express these fears. To show our good faith, we will vote for the bill to be sent to committee. My intention is not to be negative. It may be a good idea, but is it the best idea? Perhaps the intentions are good. The intention is still there. However, perhaps some amendments could be introduced. The minister may find that it is a good idea to have certain safeguards, for example.

We are worried about the criteria from the International Conference on Harmonization of Technical Requirements. We know very well that it wishes to reduce regulation. It would like to shorten the approval process for drugs and lower standards of protection in order to reduce drug development costs and the time required to bring drugs to market.

It is well known that Health Canada collaborates with this organization. Therefore, we simply want to establish certain safeguards. I believe that one of our responsibilities when studying the bill is to shed some light and ensure that we all understand what the witnesses have come to tell us.

Food and Drugs ActGovernment Orders

4:35 p.m.

Liberal

Larry Bagnell Liberal Yukon, YT

Mr. Speaker, I know government representatives are in the lobby watching this on TV. I would ask if the department could answer my two emails in writing, the one I referred to in my last question and the one I will read now. I also would like the member to answer these questions as well.

The email states:

The consequences of this Bill from, what I can understand, are far reaching. The search and seizure, as well as the fine possibilities are frankly scary. I feel that this Bill could be trying to limit our access to natural food products and potentially put natural food stores out of business. In these days of recession, this is hardly time to be putting legitimate businesses into receivership, not to mention the risk to Canadian rights and freedoms.

Here are my questions:

Will this new law be used to abuse and punish special interest groups, minorities, religious groups or others?

Why do bureaucrats want to bypass Parliament and Senate's approval to create new laws?

Why do bureaucrats want seizure warrants without judge approval?

With fines being increased a 1000 times, and seizing authority without a warrant, is Bill C-51 meant to bankrupt and silence its target audience?

Could the member provide some answers for my constituent who sent this email to me?

Food and Drugs ActGovernment Orders

4:40 p.m.

Bloc

Christiane Gagnon Bloc Québec, QC

Mr. Speaker, I believe that the goal of this bill is to reassure the public about food safety, the safety of therapeutic products and the safety of products for sale on the market to ensure that they do not contain toxic elements.

The industry must therefore conform to certain standards. We currently import many products from other countries that may not have the same standards as Canada does. We need to strike a balance with the viability of a company.

In the newspapers over the past number of months, we have seen recalls for toys and medications that put many peoples' lives in danger. In some cases, people did die. In my opinion, a balance must be struck. As the member said, if searches are conducted without a judge's approval, we should look at this in committee.

In my opinion, when a company puts peoples' lives in danger, we have to put the safety of people before the viability of a company that has been delinquent in terms of standards, regulations and the law. I believe this protects us.

Food and Drugs ActGovernment Orders

4:40 p.m.

Conservative

The Acting Speaker Conservative Andrew Scheer

It is my duty pursuant to Standing Order 38 to inform the House that the questions to be raised tonight at the time of adjournment are as follows: the hon. member Rimouski-Neigette—Témiscouata—Les Basques, Private Lumber Producers; the hon. member for Kitchener Centre, Ethics.

Food and Drugs ActGovernment Orders

4:40 p.m.

NDP

Judy Wasylycia-Leis NDP Winnipeg North, MB

Mr. Speaker, I am pleased to join in the first round of debate on Bill C-51, a bill to amend, in large measure, the Food and Drugs Act.

I bring to this debate a lot of skepticism but it is a healthy dose of skepticism based on the history of this whole aspect of Health Canada and our regulatory regime in Canada.

It will be no surprise to the House to learn that this is the fifth attempt by government in the last decade to overhaul the Food and Drugs Act. Four times before the Liberals attempted to do so and each time they failed. Why? They failed because the community spoke up and demanded more accountability from government and much clearer answers around accountability and regulatory authority.

Members will recall Bill C-80, a draft piece of legislation that was supposed to do much of what we have before us today. That bill was supposedly attempting to modernize our food and drug provisions, bring us into the 21st century and bring our rules and our regulations in line with modern day science.

It did not take too long for Canadians to quickly figure out that this was a ruse. It was an attempt to make Canadians believe the government would be on their side but was in fact loosening its hold over regulations, minimizing its role and moving us away from what has been an entrenched part of our history, and that is a bill that regulates the safety of food and drugs in such a serious manner that it is part of the Criminal Code.

That legislation operated on the basis of the do no harm principle, the precautionary principle, which means that we do not allow products on the market unless there is evidence that they are safe beyond a reasonable doubt. That is the do no harm principle. It is not the buyer beware principle. It is not the risk management model that we have seen with the Liberals before and with the Conservatives today.

There is a marked difference between the do no harm principle and the risk management model. Do no harm means that we put people and safety first. The risk management model means that we can only go so far in ensuring Canadians' safety so we will allow the products on the market and then we will see what happens. It will be up to individual Canadians to determine whether or not it is worth taking the risk. It will be up to the corporations that produce the products to regulate themselves and decide if they are in line with the standards on paper.

The risk management model is not a proactive regulatory model that puts the needs and concerns of Canadians first. It is a model that puts the needs of big pharma, large corporations and global capital forces ahead of ordinary citizens. It is a model that makes guinea pigs out of Canadians.

We have had our share of offering up people as guinea pigs for large pharmaceutical corporations. I do not need to tell the House about the incidents in our past, especially when women were treated as guinea pigs. Thalidomide comes to mind as does Depo-Provera, breast implants and the list goes on.

We need to ask ourselves some questions. If we cut through all the rhetoric and tough talk about putting safety first and modernizing our system, are we better off? Are we any closer to the kind of system that Canadians thought we had and expected to have, which was abandoned by the Liberals?

It was abandoned when, in 1997, the former minister of health, Allan Rock, in his first gesture as minister of health, killed the federal drug laboratory, the only independent federal research lab in this country for testing on a post-market surveillance basis. It tested whether drugs that were on the market were safe and whether there were any negative consequences when that drug was combined with certain foods, other drugs or natural health products. It was a lab that performed a very important safety function in our country.

That was the beginning of a whole string of actions taken by the then minister of health, Allan Rock, and subsequent Liberal ministers of health to dismantle our regulatory system and move us away from the do no harm model toward a system where corporations pay for their drug approval processes. The bulk of the fees for our drug approval process comes from the corporations themselves.

Scientists at Health Canada have seen numerous incidents and they said that enough was enough. I think of Dr. Michèle Brill-Edwards who spoke up about being cornered to approve something she thought was not safe. She had to leave Health Canada to have any sense of integrity intact.

There were many others. Who can forget the whole group of veterinary scientists who stood tall about the tampering with food products and the adulteration and modification of veterinarian drugs? They were chastised, disciplined and lambasted by the Liberal government.

Whatever happened to the government being a bastion of independent, objective science that operated on the basis of the constituents it is supposed to serve? Whatever happened to government for the people, by the people and of the people? Nowhere is this more important than when it comes to the food we eat, the drugs we take because of medical conditions and the water we drink to sustain us and yet in those areas the government has abandoned us in large measure.

Today we are supposed to believe that the Conservative Government of Canada has such integrity, courage and vision that it is offering us a blueprint for a do no harm precautionary model around drugs and food. I bring to this debate a dose of healthy skepticism because I have seen nothing from the Conservatives to date that leads me to believe that the government is on the side of ordinary Canadian families and is not on the side, first and foremost, of the big corporations and their profit margins.

I have not seen that when it comes to housing, education, health care, women's equality, people with disabilities, the environment, jobs and child care. I have not yet seen the government stand up for Canadians

Food and Drugs ActGovernment Orders

4:45 p.m.

NDP

Irene Mathyssen NDP London—Fanshawe, ON

Nor will we.

Food and Drugs ActGovernment Orders

4:45 p.m.

NDP

Judy Wasylycia-Leis NDP Winnipeg North, MB

My colleague from London—Fanshawe says, “Nor will we”. That is why I bring to this debate my concerns.

However, that is not to say that there are not some good provisions in this bill. I do recognize that the government has moved a significant distance from the days of the Liberals. Ironically, this legislation is more proactive than the Liberals ever presented to this House. However, it still has lots of problems and it still does not mean we will be supporting it but it is a step forward.

I would like to point to a couple of those initiatives. The bill has provisions for the recall of drugs and food products that have contaminants. The bill sets out hefty fines for corporations that do not reveal problems or side effects with drugs. There is new emphasis in this bill around ensuring that government has the tools to protect Canadians. I commend the government for those initiatives and I support those aspects of the bill that take us forward toward what I consider fundamental to this whole debate and that is a do no harm approach when it comes to food and drugs.

However, beneath those specific clauses and the fine words of the press release that the Prime Minister and the Minister of Health presented to Canadians about safety first, there are enough concerns to make me and others suspicious of what the government is all about and where it is trying to lead us.

We only need to look at a couple of the areas that we have heard about to date. I hear some of my colleagues on the Conservative benches chuckling. I do not think they would chuckle if they were to listen to the words of Dr. Barbara Mintzes, who has brought to the attention of the House a clause in the bill that appears to move the government closer to direct to consumer advertising. That is so well documented that some of the officials have already said that they acknowledge that is a problem and maybe it needs to be addressed.

Why is that important? Do we want to see another $6.3 billion added to our pharmacare bill? Do we want to see big pharma pushing their drugs on Canadians without scientific basis? Do we want to see full-blown advertising in this country, as is the case in the United States?

Is it not enough that we have this grey area where drug companies can find a loophole and advertise all they want the lifestyle and create the appearance of something helping this person without naming the drug. We need only to look at the Viagra ads. They are pretty clear and impressive and they have led to all kinds of people demanding prescriptions for certain drugs from their doctors without necessarily a basis in terms of either their condition or the science available.

Direct to consumer advertising is just one of the problems in the bill that will make us very cautious about supporting it. Unless this loophole is closed and there is a firm commitment from the government to absolutely close the door to direct to consumer advertising, which not only means where we are today but going back and closing the door in terms of the loophole, there is no way in the world we should support the bill because of the ramifications it would have for our entire health care system, a system where costs for pharmaceuticals are now outstripping all other aspects of the system.

I will give another example. We have heard mentioned in the Chamber today the words “lifecycle approach” to drug surveillance or “progressive licensing”. It all sounds great, innovative and progressive but we need to realize that underneath it all there could very well be an agenda to speed up the approval of drugs at the front end and create the illusion of safety or the reality of safety at the other end.

However, what does it matter when we have already digested a drug that is not safe and has produced serious health consequences? Can it be that the government has listened to the drug companies when they say that they would rather deal with expensive lawsuits and pay out big money after being sued than to put in the money that is needed at the front end to ensure that the drugs are safe in the first place?

The real question we have to ask today is the one Alan Cassels and others asked in the media when the bill was released. Would this bill prevent another Vioxx? Would it stop a situation where hundreds of thousands of people are dying because they took a drug without realizing there were serious side effects unrelated to the condition for which they were taking it? What in this bill would stop that? Where is the inspection force? Where is the apparatus? Where is the infrastructure to make that happen? Where is the commitment from the government to deal with contaminated drugs coming into this country? How will the government handle another heparin, a contaminated drug from China? Is it prepared to send inspection officers to manufacturers in China? Is it prepared to put surveillance officers at the border? Is it prepared to take seriously the side effects that Canadians talk about? Is it prepared to act the minute there are serious reactions to drugs?

I hope that is the case. I do not know if that is the case. I do not know if this bill would do that. I want to keep an open mind about that. When we get to committee, I want to ask those questions. Witnesses will testify. We are going to seriously study that aspect. The fundamental bottom line when it comes to this bill is, is it going to stop another Vioxx? That is the question. How will it do it? Will it do it in time? Will it really make drug companies provide the information that they may have held in secret which may reveal something? Would it have been able to get out of Merck Frosst the information around Vioxx that it kept secret that would have prevented hundreds of thousands of deaths?

Those are two areas of concern. There are others.

We have received hundreds of letters from people concerned about natural health products. We have been inundated with letters and communications expressing concern about this bill and whether or not there is a hidden agenda to bring natural health products under the rubric of drugs, after the huge battle we have had in this House for a decade to have a separate category for natural health products. This is something that the Conservatives took up with a vengeance some 10 years ago, which led to a health committee discussion and a report, which led to the establishment of a third category, which led to some reasonable approach to dealing with natural health products. Unfortunately, both the Liberals and the Conservatives since then have botched the whole plan. We now have hundreds of thousands of natural health products waiting in line to be assessed and licensed.

The question here is, is this a way to get around that? Is this an attempt to deal with the backlog like we have seen with immigration? Perhaps it is similar to the budget implementation bill and slipping immigration into that bill. We do not know.

Needless to say, when it comes to this area, there is nothing more important than how we protect people in terms of the drugs and the medications they have to take and the food they have to eat. It is the job of government to put safety first, to ensure that products on the market are as safe as possible. That means a proactive government, tough regulations, adequate resources, a government with the will to make safety fundamental and to put people before drug profits.

Food and Drugs ActGovernment Orders

5 p.m.

Conservative

Brian Fitzpatrick Conservative Prince Albert, SK

Mr. Speaker, I was astounded to listen to the member's presentation and the one from the Bloc as well. I have come to the conclusion that maybe we should have a special law that prohibits big corporations from distributing and selling prescription drugs to NDP members and their supporters, and maybe Bloc members as well, because we would not them to take something they feel is unscientific and would not have any benefit.

Let us be clear. For every drug cleared through the clinical trial process, there are literally thousands of drugs that do not get to first base. This is not a slam dunk process and it costs an awful lot of money. There are a lot of other safeguards. The EU has a clinical process that is very tough. The Japanese have one that is very tough. The Americans have one that is very tough. If manufacturers fail in the United States, they get through the entire process and get a drug approved but if they make a mistake, they can be financially ruined by the American tort system.

However, for members of this House to say that we are just allowing drugs on to market without any due diligence or any comprehension for public safety and that there is some great conspiracy between members of Parliament and the drug companies to foist all these poisonous and toxic drugs on people is total nonsense. I cannot believe the member actually believes that. I do not want to disagree too strongly with her opinion because it might insinuate that I am challenging her intelligence.